Antibody Drug Conjugate Market 2019 Analysis - Research Covers Top 10 Players as ImmunoGen, Inc., Roche Holding AG, Concortis Biotherapeutics, Agensys, Inc., Antikor, Millennium Pharmaceuticals
Antibody Drug Conjugate Market - Market Insights
These drug conjugates are regarded as the new age of therapeutic agents. The efficiency of the drug in treating diseases has propelled demand in the global market, and the trend is likely to perpetuate over the next few years. The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers.
The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.
Get PDF Sample Copy @ https://www.marketresearchfuture.com/sample_request/1113
Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.
Antibody Drug Conjugate Market - Segmentation
By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).
By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
Antibody Drug Conjugate Market - Competitive Dashboard
Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).
Antibody Drug Conjugate Market - Regional Analysis
By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.
Antibody Drug Conjugate Market - Industry Developments
In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.
Browse Complete 140 Pages Premium Research Report Enabled with 96 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
Major Points from Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global Antibody Drug Conjugate Market, By Type
Chapter 7. Global Antibody Drug Conjugate Market, By Application
Chapter 8. Global Antibody Drug Conjugate Market, By Product
Chapter 9. Global Antibody Drug Conjugate Market, By Technology
Chapter 10. Global Antibody Drug Conjugate Market, By End-User
Chapter. 11 Global Antibody Drug Conjugate Market, By Region
Chapter 12 Company Landscape
Chapter 13 Company Profiles
Chapter 14 MRFR Conclusion
Chapter 15 Appendix
Get Prime Discount at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Phone: +1 646 845 9312
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody Drug Conjugate Market 2019 Analysis - Research Covers Top 10 Players as ImmunoGen, Inc., Roche Holding AG, Concortis Biotherapeutics, Agensys, Inc., Antikor, Millennium Pharmaceuticals here
News-ID: 1489737 • Views: 559
More Releases from Market Research Future
Clinical Trial Management System Market Demand, Industry Share, Size, Applicatio …
Clinical Trial Management System Market Analysis by Type (Enterprise Clinical Trial Management System), Delivery Model (Licensed Enterprise), Component (Service) and End-User (Medical Device Manufacturers), and Regional Competitive Share, Size and Trends, 2018-2023 Market Overview Clinical Trial Management System Market is mostly a software system which helps to plan, prepare, and manage a large amount of clinical trials data that is produced by biotechnological and pharmaceutical companies. Drug research has gained momentum in
Reusable Satellite Launch Vehicle (RSLV) Market 2019-2023 | Report Information b …
Global Reusable Satellite Launch Vehicle Market Report Information by Configuration (Single Stage, Multiple Stage), by Type (Partially Reusable, Fully Reusable), Vehicle Weight (Up to 4,000lbs, 4000-9000lbs, Over 9000lbs), & by Region - Forecast Till 2023 The Reusable satellite launch vehicle market is estimated to witness a CAGR of more than 12% during the forecast period from 2018 to 2023. The key players in the reusable satellite launch vehicle market are Airbus S.A.S
Bakery Enzymes Market Global Research Report and Top Key Players: AB Enzymes Gmb …
Market Overview The increasing demand for bakery products in the food and beverage industry including, bread, cookies, and pastries are raising the demand for bakery enzymes at a global level. Enzymes are an important ingredient used in most bakery products. There are two scenarios regarding the use of enzymes, either the enzymes are used to convert the raw material into the main product, or the enzymes are used as additives to
Commercial Airport Lighting Market 2019-2023 | Worldwide Overview By Technology, …
Global Commercial Airport Lighting Market Research Report: Information by Technology (LED, Non-LED), by Application (Airside Lighting, Terminal Lighting, Landside Lighting), and by Region — Forecast till 2023 Honeywell International Inc., (US), ADB SAFEGATE (US), ABB (Switzerland), vosla GmBH (Germany), Avlite (Australia), Carmanah (Canada), Eaton (Ireland), atg airports limited (UK), Avionics Group (US), and HELLA GmBH & Co. KGaA (Germany) are some of the prominent players profiled in MRFR Analysis and are
More Releases for Antibody
Global Antibody Drug Conjugates Market Insights, Forecast
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement
Procalcitonin Antibody Market Opportunity Analysis, 2018 - 2026
Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, and belongs to calcitonin (CT) superfamily of peptides. Procalcitonin is a 116 amino acid peptide that has an estimated molecular weight of 14.5 kDa. It can be segregated into three parts, namely immature calcitonin, calcitonin carboxyl-terminus peptide-1, and amino terminus of the PCT region. Procalcitonin was first classified by Bernard Roos and Leonard J. Deftos in the early 1970s. Procalcitonin
Procalcitonin Antibody Market
Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E.coli Scope of the Report: This report focuses on the Procalcitonin
Global Combination Antibody Therapy Market | MarketResearchReports.biz
Latest industry research report on: Global Combination Antibody Therapy Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts In its recently published report titled Combination Antibody Therapy Market: Global Industry Analysis and Forecast, 2016-2024, Persistence Market Research reviews the global combination antibody therapy market for an eight year forecast period (2016 2024). This research report provides a detailed analysis of the global combination antibody therapy market
Antibody Drug Conjugate Market Opportunity Analysis
Ever since the first attempt in the 1980's to use antibody-based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the
Global Antibody Drug Conjugate Market & Pipeline Insight2020
Pharmaceutical companies are trying to develop better therapeutics in order to overcome large unmet medical necessities. Currently available therapeutics suffers from various caveats like low specificity, low potency and severe adverse effects. This scenario has caused the pharmaceutical companies to develop therapeutics that can succeed these limitations. They have been able to overcome these problems and improve their medical conditions by commercializing ADC. They are rapidly gaining acceptance across the